Filing Flows › Krystal Biotech (KRYS) › Q2 2026 › vs Q1 2026
Krystal Biotech (KRYS) Q2 2026 vs Q1 2026 (quarter over quarter)
Krystal Biotech's revenue rose $2.9M (+2%) from $116M in Q1 2026 to $119M in Q2 2026. Operating margin 49.0% against 46.1% (+2.9 pts).
Krystal Biotech, Q2 2026: revenue $119M (+24% year over year), operating margin 49.0%, net earnings $54.8M, operating cash flow $74.8M. The chart draws each line against Q1 2026, the increases inside each band.
Margins
| Q2 2026 | Q1 2026 | Change | |
|---|---|---|---|
| Operating margin | 49.0% | 46.1% | +2.9 pts |
| Net margin | 45.9% | 48.1% | -2.1 pts |
| Free cash flow margin | 59.7% | 62.9% | -3.2 pts |
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $119M | $116M | $2.9M | +2% |
| Other income, net | $7.7M | $7.8M | −$91K | -1% |
| Operating profit | $58.4M | $53.7M | $4.7M | +9% |
| Costs & expenses | $60.8M | $62.7M | −$1.9M | -3% |
| Pre-tax earnings | $66.1M | $61.4M | $4.6M | +8% |
| Research & development | $14.5M | $15.3M | −$813K | -5% |
| SG&A | $39.9M | $41.0M | −$1.2M | -3% |
| Other operating costs | $6.4M | $6.3M | $114K | +2% |
| Net earnings | $54.8M | $55.9M | −$1.2M | -2% |
| Income tax | $11.3M | $5.5M | $5.8M | +105% |
| Depreciation | $1.4M | $1.5M | −$122K | -8% |
| Share-based compensation | $14.2M | $13.6M | $547K | +4% |
| Working capital & other | $4.5M | $9.3M | −$4.9M | -52% |
| Operating cash flow | $74.8M | $80.4M | −$5.6M | -7% |
| Free cash flow (OCF − capex) | $71.2M | $73.2M | −$2.0M | -3% |
| Capital expenditures | $3.6M | $7.1M | −$3.6M | -50% |
Questions
How much did Krystal Biotech's revenue grow quarter over quarter in Q2 2026?
Krystal Biotech's revenue rose $2.9M (+2%) from $116M in Q1 2026 to $119M in Q2 2026. Operating margin 49.0% against 46.1% (+2.9 pts).